Peyriere Hélène, Cociglio Marylène, Margueritte Geneviève, Vallat Catherine, Blayac Jean-Pierre, Hillaire-Buys Dominique
Department of Medical Pharmacology and Toxicology, Lapeyronie Hospital, Montpellier, France.
Ann Pharmacother. 2004 Mar;38(3):422-7. doi: 10.1345/aph.1D237. Epub 2004 Jan 23.
To describe the time course and management of methotrexate (MTX) toxicity in a 14-year-old Hispanic boy with osteosarcoma treated with high-dose MTX.
During the sixth cycle of high-dose MTX, severe intoxication was observed with high MTX plasma concentrations, acute renal failure, and hepatitis, followed by mucositis and moderate myelosuppression. Intensification of urine alkalinization and increased leucovorin dosages did not decrease plasma concentrations of MTX or prevent systemic toxicities. Carboxypeptidase G2 and aminophylline were thus administered as a second-intention rescue strategy. Within 2 weeks, a recovery of clinical symptoms and normalization of the biological abnormalities were observed. Limb salvage surgery was performed, which permitted classifying the patient as an MTX high-responder. Thereafter, MTX was successfully resumed, leading to clinical recovery of the patient. Concomitantly, homocysteine plasma levels, a marker of the pharmacodynamic effect of MTX, were measured. During the intoxication, homocysteine plasma levels were significantly increased, parallel to the excessive MTX plasma concentrations observed.
According to the excessive MTX levels measured in this patient, along with the observed clinical (mucositis) and biological (hepatitis, renal injury) adverse effects, we suggest that MTX may be a cause of these complications. Use of the Naranjo probability scale indicated a probable relationship between the complications and MTX.
This observation shows that severe complications observed during one cycle of high-dose MTX is not predictive of the tolerability of further courses. Optimal management of such complications, using specific therapeutic intervention, may be considered.
描述一名接受大剂量甲氨蝶呤(MTX)治疗的14岁西班牙裔骨肉瘤男孩的MTX毒性的时间进程及处理情况。
在大剂量MTX治疗的第六周期,观察到严重中毒,伴有MTX血浆浓度升高、急性肾衰竭和肝炎,随后出现黏膜炎和中度骨髓抑制。强化尿液碱化和增加亚叶酸剂量并未降低MTX血浆浓度或预防全身毒性。因此,给予羧肽酶G2和氨茶碱作为二线抢救策略。2周内,观察到临床症状恢复,生物学异常指标恢复正常。进行了保肢手术,这使得该患者被归类为MTX高反应者。此后,成功恢复使用MTX,患者临床康复。同时,检测了作为MTX药效学效应标志物的血浆同型半胱氨酸水平。中毒期间,血浆同型半胱氨酸水平显著升高,与观察到的MTX血浆浓度过高平行。
根据该患者检测到的MTX水平过高,以及观察到的临床(黏膜炎)和生物学(肝炎、肾损伤)不良反应,我们认为MTX可能是这些并发症的原因。使用纳伦霍概率量表表明并发症与MTX之间可能存在关联。
该观察结果表明,在一个大剂量MTX周期中观察到的严重并发症并不能预测后续疗程的耐受性。可考虑使用特定治疗干预措施对此类并发症进行最佳处理。